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Abstract
Purpose Evidence suggests a two-pronged role of endoge-
nous macrophage migration inhibitory factor (MIF) release
in ischemia/reperfusion injury. We aimed to assess whether
its exogenous administration confers cardioprotection.
Methods Male C57/BL6 mice were randomly allocated to
receive recombinant mouse MIF (rMIF) at physiological
(ng/mL) concentrations in a dose–response fashion before or
after a protocol of 35min of ischemia and 2 h of reperfusion in
an isolated Langendorff-perfused model with infarct size as
endpoint. Isolated primary cardiomyocytes were also used for
cell survival studies using rMIF at a supra-physiological con-
centration of 1 μg/mL. Pro-survival kinase activation was also
studied using Western blot analyses.
Results ExogenousMIF did not elicit a cardioprotective effect
either when administered before the ischemic insult or when
applied at reperfusion. rMIF did not confer protection when it
was applied immediately before or after a hypoxia/reoxygenation
insult in primary isolated cardiomyocytes. Consistently, hearts
treatedwithMIF did not show a significant increase in phosphor-
ylated Akt and ERK1/2.
Conclusion The exogenous administration of rMIF in a phys-
iological concentration range both before ischemia and at re-
perfusion did not show cardioprotective effects. Although
these results do not address the role of endogenous MIF after
an ischemic insult followed by reperfusion, they may limit the
potential translational value of rMIF.
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Background
Acute myocardial infarction (AMI) is a leading cause of mortal-
ity and morbidity worldwide. Early coronary reperfusion limits
infarct size (IS) and improves prognosis. Paradoxically, reperfu-
sion itself induces additional damage to the myocardium, known
as ischemia/reperfusion injury (IRI) [1]. Further IS-limiting ther-
apies beyond early reperfusion are needed, since IS is the main
prognostic determinant in post-AMI patients [2].
Macrophage migration inhibitory factor (MIF) is a pleio-
tropic inflammatory cytokine with chemokine-like functions
[3], but also cell-intrinsic roles in cell stress and survival. MIF
is expressed by cardiomyocytes in the heart, and its secretion
from the heart is triggered after an ischemia–reperfusion insult
[4, 5], potentially affecting myocardial function [6].
Endogenous MIF has emerged as a key player in
cardioprotection of myocardial IRI [7]. Its cytoprotective role
has been mainly studied inMif-deficient mice, demonstrating
that the lack of this cytokine increases the injury caused after
an ischemic insult followed by reperfusion, whilst exogenous
MIF administration in those knockout (KO) mice restores the
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amount of injury to that observed in the wild types (WT).
Endogenous MIF appears to confer cardioprotection through
several mechanisms: 1) AMPK activation through interaction
with the cell surface receptor CD74, promoting glucose up-
take in the heart [4]; 2) inhibition of JNK-mediated apoptosis
[8]; and 3) MIF’s own antioxidant properties [9], further in-
creased with a S-nitros(yl)ation modification of MIF at cyste-
ine 81 residue [10].
MIF also activates PI3 kinase in different cell types
[11–13]. It is well known that Akt and ERK act as survival
proteins and form part of the well described Reperfusion
Injury Salvage Kinase (RISK) pathway [1]. Activation of
this signaling cascade has been associated with protec-
tion from I/R injury by both the conditioning phenom-
enon and a range of pharmacological agents. As such
our hypothesis proposes that MIF by activating PI3 ki-
nase and ERK1/2 would have a beneficial effect on the
heart following IRI.
Preliminary data indicate that MIF is involved in the mo-
lecular mechanisms of anaesthetic induced preconditioning
[14]. Even small-molecule MIF agonists enhancing MIF-
mediated AMPK-activation have been developed as a poten-
tial therapeutic drug [15]. However, whilst the administration
of recombinantMIF in a murine in vivomyocardial I/R setting
reversed the increased infarct size seen in Mif-deficient mice
[10], the cardioprotective efficacy of MIF administered in an-
imals without genetic manipulation has not been elucidated.
The confirmation of an IS-limiting effect after an exogenous
MIF administration would have a significant translational
value.
While some clinical findings showed MIF’s organoprotective
effects in patients exposed to myocardial I/R following cardiac
surgery [16], some in vivo and clinical studies have suggested
deleterious properties of MIF release after an AMI. For example,
elevated MIF blood levels after an AMI have been positively
correlated with IS and negatively associated with the extent of
cardiac remodeling [17]. In addition, as MIF is a cytokine
playing an important role in the inflammatory response that oc-
curs early after AMI [6], it has been suggested thatMif deficiency
confers cardioprotection from prolonged IRI by suppressing
these responses [9, 18], whilst it actually does the contrary effect
after a shorter ischemic insult. These paradoxical results are po-
tentially explainable, because the inflammatory response is a
prerequisite for adequate healing and scar formation, that may
become adverse if persistent [19]. Moreover, in other settings
where there is significant MIF release, such as in sepsis, MIF
has shown cardio-depressant properties [20, 21].
All this evidence points towards to a two-pronged role of
endogenous MIF, although the key question, with further
translational value, of whether its exogenous administration
is cardioprotective when applied to wild-type animals remains
unanswered. Hence, the aims of this study were (1) to analyze
the effect of the exogenous administration of MIF on IS in a
dose–response fashion, using physiological concentrations of
MIF, either applied before or after an ischemic insult, (2) to
analyze whether a very high dose of MIF confers greater pro-
tection at cardiomyocyte level, and (3) to study the RISK
signaling pathway activation after the exogenous administra-
tion of MIF.
Methods and Materials
Animals and Chemicals
Animals used were male C57BL/6 mice (9–12 weeks, 24–
28 g weight). Recombinant mouse MIF (rMIF) and bradyki-
nin were purchased from Biolegend (London, UK) and
Sigma-Aldrich (Poole, UK), respectively. The bioactivity of
rMIF was tested by the company using a bioassay that studied
the migration of THP-1 cells in a trans-well experimental sys-
tem. Doses of rMIF were chosen by evaluation of those ap-
plied inMif-deficient mice in previous publications [8, 22] as
well as its physiological plasma levels range [7, 17].
Bradykinin concentration dose administered at reperfusion
was based on previous publications [23]. Dimethyl sulfoxide
from BDH (Poole, UK) was used as the solvent for
Bradykinin at a final concentration in the perfusion buffer of
not more than 0.01 %.
Study Design and Study Protocol
Four sequential sets of experiments were performed, requiring
the use of 80 animals: 68 were allocated for perfusion
experiment purposes (4 of them were excluded before
randomization as they fulfilled pre-defined exclusion
criteria), 3 were used for cardiomyocyte isolation, and
finally 9 were used to collect samples for Western blot
analyses. Hence, the study was divided into four con-
secutive parts, as illustrated in Fig. 1:
1) Effect on myocardial IS of the exogenous MIF adminis-
tration before ischemia (Fig. 1a). Thirty-eight mice were
allocated according to a randomized block design into the
following groups: 1) Control; 2) ischemic precondition-
ing (IPC); 3)MIF 1 ng/mL; 4)MIF 10 ng/mL; and 5)MIF
50 ng/mL. IPC was induced by 4 cycles of 5 min global
ischemia and 5 min reperfusion prior to index ischemia.
MIF was applied 15 min before ischemia.
2) Effect on myocardial IS of the exogenous MIF adminis-
tration upon reperfusion (Fig. 1a). Thirty mice were ran-
domized into 5 groups to evaluate the effects of: 1)
Control; 2) Bradykinin 100 nM/L; 3) MIF 1 ng/mL; 4)
MIF 10 ng/mL; and 5) MIF 50 ng/mL. All MIF groups
received the therapy immediately at reperfusion during
15 min.
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3) Effect on percent of cell death of high-dose MIF admin-
istration in normoxia and hypoxia/reoxygenation (H/R)
protocols in adult mouse cardiomyocytes. Three animals
were used for cardiomyocyte isolation. Cardiomyocytes
were randomly allocated into 5 groups (2 wells per
group): (1) Normoxic control, (2) Normoxic MIF 1 μg/
mL, (3) H/R control, (4) H/R with 1 μg/mL MIF before
the hypoxic insult, and (5) H/R with 1 μg/mL MIF at
reoxygenation.
4) Effect on ERK and Akt phosphorylation after the exoge-
nous MIF administration in a Langendorff-perfused
mouse heart model. Hearts destined forWestern blot anal-
yses were allocated in 3 groups: (1) Control, (2) IPC, and
(3) MIF 50 ng/mL.
Ex Vivo Isolated Langendorff-Perfused Mouse Heart
Model of Acute Myocardial Infarction
Mice were given terminal anesthesia and anticoagulation with
an intra-peritoneal injection of 60 mg/kg sodium pentobarbi-
tone and 100 IU heparin, respectively. The heart was harvest-
ed and immediately submerged in ice-cold modified Krebs–
Henseleit buffer (see below composition). The aorta was
swiftly cannulated with a 21-gauge cannula and the heart ret-
rogradely perfused on a murine Langendorff perfusion appa-
ratus at 80 mmHg pressure.
Heart isolation and Langendorff perfusion were carried out
with filtered modified Krebs–Henseleit buffer (composed of
118 mmol/L NaCl, 25 mmol/L NaHCO3, 11 mmol/L glucose,
Fig. 1 Study design and
protocols. A black box represents
a period of ischemia, whilst a
white box represents a period of
perfusion with Krebs–Henseleit
buffer at 80 mmHg. A grey box
represents the perfusion of MIF
through the perfusion apparatus.
The black arrows show the time
point the samples for Western
Blot analysis were taken. * In
total, 3 animals were used to
isolate cardiomyocytes and
allocate them in 5 separate groups
in each isolation. Abbreviations:
H/R, hypoxia/reoxygenation;
IPC, ischemic preconditioning;
MIF, macrophage migration
inhibitory factor
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4.7 mmol/L KCl, 1.22 mmol/L MgSO4.7H20, 1.21 mmol/L
KH2PO4, and 1.84 mmol/L CaCl2.2H20) aerated with a mix-
ture of O2 (95 %) and CO2 (5 %) in order to maintain pH at
7.42 ± 0.3, as previously described [24, 25]. After the assess-
ment for exclusion criteria in an initial stabilization pe-
riod of 20 min, each Langendorff perfused mouse heart
was randomly assigned to one of the study protocols
illustrated in Fig. 1a.
Pre-defined exclusion criteria were: 1) time between cessa-
tion of blood circulation and the start of perfusion in the
Langendorff mode greater than 4 min, 2) temperature above
or below the 37 ± 0.2 °C range, 3) flow rate of less than 1 mL/
min or more than 6 mL/min on the Langendorff preparation
during the stabilisation period.
All hearts were subjected to 35min global ischemia and 2 h
reperfusion prior to determination of IS by 2,3,5-triphenyltet-
razolium chloride (TTC) staining.
Myocardial Infarct Size Analysis
After global normothermic ischemia, IS was determined by
injecting 5 mL of TTC in phosphate-buffered saline through
the aortic cannula and incubating the heart for 10 min at 37 °C
in order to demarcate the infarcted (white) versus viable (red)
tissue [26]. After the incubation, the heart was weighed and
then frozen overnight at −20 °C. Following this, it was sec-
tioned perpendicular to the long axis and the slices transferred
into 10 % neutral formalin buffer for 1 h.
Images were thereafter coded in order to blind the analyser.
Planimetry analysis using Image J version 1.47 (NIH,
Bethesda, MD) was carried out to accurately quantify the per-
centage IS in each heart as a proportion of the total heart
volume.
Isolation of Adult Mouse Cardiomyocytes
Ventricular cardiomyocytes were isolated from mouse hearts
using Liberase digestion as described previously [27]. Briefly,
hearts were excised and cannulated through the aorta before
retrograde perfusion on a modified Langendorff system at
37 °C. Perfusion buffer consisted of NaCl 113 mmol/L, KCl
4.7 mmol/L, KH2PO4 0.6 mmol/L, Na2HPO4 0.6 mmol/L,
MgSO4-7H2O 1.2 mmol/L, NaHCO3 12 mmol/L, KHCO3
10mmol/L, Hepes Na salt 0.922mmol/L, Taurine 30mmol/L,
2,3-butanedione-monoxime 10 mmol/L, Glucose 5.5 mmol/L
(pH 7.4). Following perfusion for 5 min to clear residual
blood, enzymatic digestion was performed with a digestion
buffer for 20 min (30 mL perfusion buffer with 5 mg
Liberase (Roche, UK) and 12.5 μmol/L CaCl2). At the end
of enzymatic digestion, both ventricles were isolated and gent-
ly disaggregated in 2 mL of digestion buffer. The resulting cell
suspension was filtered through a 100 μm mesh and trans-
ferred for enzymatic inactivation to a tube with 10 mL of
stopping buffer (perfusion buffer supplemented with fetal bo-
vine serum (FBS) 10 % and Ca2+ was gradually re-introduced
with three progressively increased CaCl2 concentration steps.
Cells were then re-suspended in M199 (Invitrogen, UK) sup-
plemented with L-Carnitine (2 mmol/L), Creatine (5 mmol/L,
Taurine (5 mmol/L) and Penicillin (100 IU/ml), Streptomycin
(100 IU/ml) and 25 μmol/L Blebbistatin.
Experimental Protocol for Mouse Ventricular
Cardiomyocyte Viability Studies
Prior to being subjected to induced hypoxia/reoxygenation,
freshly isolated adult mouse cardiomyocytes were plated and
stabilized for 1 h at 37 °C with M199 medium with the fol-
lowing supplements: creatine 5 mM, carnitine 2 mM, taurine
5 mM and penicillin/streptomycin (100 x). Cells were there-
after randomly allocated in each group and the medium was
changed to normoxic buffer for 1 h, prior to being subjected to
30 min of hypoxia and 1 h of re-oxygenation to simulate IRI.
MIF was administered in combination with normoxic buffer
according to the protocol illustrated in Fig. 1b. Hypoxia was
induced in an airtight hypoxic chamber using a buffer simu-
lating the conditions of ischemia (in mM: 1.2 KH2PO4, 2.2
NaHCO3, 1.2 MgSO4, 127.8 NaCl, 14.8 KCl, 1 CaCl2 and 10
Na lactate, pH 6.4) bubbled with 95 % N2/5 % CO2. Re-
oxygenation was achieved by replacing the buffer with the
normoxic buffer (containing in mM: 1.2 KH2PO4, 22
NaHCO3, 1.2 MgSO4, 118 NaCl, 2.6 KCl, 1.2 CaCl2 10.0
D-glucose; pH 7.4) bubbled with 95 % O2/5 % CO2. At
the end of the re-oxygenation, the cells were stained with
1 mg/mL stock propidium iodide (PI) and imaged using a
fluorescent microscope – red channel for PI and phase contrast
for total cell population. The percentage of dead cells (as
indicated by red fluorescence, PI-positive) in duplicate wells
was calculated by fluorescencemicroscopy andwas expressed
as a percentage of the total number of cardiomyocytes.
Western Blot Analysis
Hearts prepared for Western blot analysis were harvested fol-
lowing those protocols illustrated in Fig. 1c, and thereafter
snap-frozen in liquid nitrogen. The tissue was then stored at
−80 °C until further processing. The tissue was homogenized
in protein lysis buffer, containing Tris pH 6.8 [100 nM], NaCl
[300 Mm], NP40 0.5%pH, Halt protease inhibitor cocktail,
Halt phosphatase inhibitor cocktail, 0.5MEDTA and adjusted
to pH 7.4. Homogenates were then briefly sonicated before
being centrifugated at 4 °C to remove debris and DNA.
Protein content was then determined using bicinchocinic aci
(BCA) protein assay reagent (Sigma, UK) and protein levels
corrected accordingly to ensure equal protein loading.
NuPAGE LDS Sample Buffer (4X) (Thermofisher
Scientific, UK) plus 5 % β-mercaptothanol were added and
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the samples were denaturated by heating to 90–100 °C for
10 min. NuPAGE Novex 10 % Bis-Tris protein gels
(Thermofisher scientific, UK) were used for electrophoresis
using the Mini Protean III system (Bio-Rad, UK). Gels were
transferred onto immobilon-FL PVDF transfer membrane
(MerckMillipore, UK) using wet transfer in a Bio-Rad Mini
Trans-Blot. The membranes were blocked by incubating in
2.5 % bovin serum albumin/PBS tween and subsequently in-
cubated with appropriate primary antibodies at 4 °C overnight.
Primary antibodies used were acquired from Cell Signaling
Technology: ERK1/2 (#9102), Phospho-ERK1/2 (Thr202/
Tyr204) (#9101), Akt (#9272), Phospho-Akt (Ser473)
(#9271). The day after, the membrane were probed with sec-
ondary antibodies with infrared fluorescent. Levels of protein
were finally quantified using the Odyssey imaging system
from Li-Cor Biosciences.
Statistical Analyses
Images were coded in order to perform a blinded assessment
of both IS and cell viability pictures. All values are presented
at mean ± standard error of the mean. One-way ANOVAwas
carried out to compare percentages between groups, followed
by post-test analysis using the Dunnett’s t-test for multiple
comparisons when using a single reference category (ex vivo
isolated Langendorff-perfused andWestern Blot results) or by
Bonferroni’s correction when performing multiple compari-
sons with different reference categories (studies of cell viabil-
ity presented two separate controls: one within the normoxic
group and another one within the H/R group). A two-sided P-
value <0.05 was considered significant.
STATA software, version 13.1 (Stata Corp, College
Station, TX, USA) and GraphPad Prism version 6.00
(GraphPad Software, La Jolla California, USA) were used to
perform the analysis and the graphics. The results were report-
ed according to the ARRIVE guidelines for reporting animal
research [28].
Results
MIF before Ischemia–Reperfusion
To determine whether rMIF is protective against IRI in mice
when applied before ischemia, a dose response curve using the
ex vivo isolated Langendorff-perfusedmouse heart model was
performed (Fig. 2). The IS after global ischemia was
31.8 ± 2.3 % in the control group, whilst the low dose of
rMIF showed an IS reduction but without statistical signifi-
cance (25.3 ± 3.5 %, P = 0.138 compared to control group).
On the contrary, neither the mid-dose nor the high-dose ad-
ministration of MIF showed any relevant difference in terms
of IS (34.7 ± 3.5 %, P = 0.998; and 30.5 ± 2.8 %, P = 0.859,
respectively). Finally, the application of a 4-cycle protocol of
IPC, as a positive control, resulted in an infarct reduction of
17.7 ± 2.2 % (P = 0.003).
MIF at Reperfusion
The exogenous administration of rMIF (1 ng/mL, 10 ng/mL
and 50 ng/mL), applied upon restoration of coronary flow
(reperfusion), did not confer any cardioprotective effect when
compared to control group (IS of 36.6 ± 2.9 %) (Fig. 3). The
low-dose of MIF did not show a significant reduction of IS
(29.3 ± 2.7 %, P = 0.223). In the same vein, neither relevant
effect was observed with the mid-dose (30.6 ± 4.9 %,
P = 0.412) nor with the higher dose of MIF (37.2 ± 0.9,
P = 0.998). A well-known cardioprotective agent was used
as a positive control (bradykinin 100 nM), resulting in a highly
significant IS reduction (16.6 ± 2.3, P = 0.001).
MIF in Isolated Cardiomyocytes
Given the unexpected results in the isolated Langendorff-
perfused model, a supraphysiologic dose of MIF was applied
in isolated cardiomyocytes without, before and after a protocol
of H/R. Isolated adult cardiomyocytes from 3 different WTmice
were allocated in 5 different groups, being subjected to either
normoxic or H/R protocols, in the presence of rMIF or its vehicle
(Fig. 4). Analysis of cell death count (expressed as a percentage)
within the normoxic groups showed a non-significant increase of
cell death after the use of a very high-dose of rMIF (normoxic
control of 24.0 ± 4.3 % vs MIF 1 μg/mL of 33.7 ± 5.6 %,
P = 0.610). Accordingly, rMIF administered before or after an
H/R insult resulted in a non-significant increase of cell death
Fig. 2 Dose–response effect of exogenous rMIF administered before
ischemia on myocardial infarct size in the ex vivo isolated Langendorff-
perfused mouse heart model (%). Bar graph showing the IS in all groups,
expressed as mean ± SEM for infarct size (%), n = 6–8 per group. Overall
P-value was 0.002, whilst in the post-hoc analysis, the control group was
compared to IPC (**P = 0.003), MIF 1 ng/mL (P = 0.138), MIF 10 ng/
mL (P = 0.998) and MIF 50 ng/mL (P = 0.859). Abbreviations: IPC,
ischemic preconditioning; MIF, macrophage migration inhibitory factor
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compared to those observed in the control group (control:
39.3 ± 3.9 %; rMIF before H/R: 47.6 ± 3.7 %, P = 0.794; and
rMIF after H/R: 55.5 ± 6.9 %, P = 0.134).
rMIF and the RISK Pathway
To assess the effect of rMIF treatment in mouse hearts, Akt
and ERK 1/2 phosphorylation were measured following its
administration through the ex vivo isolated Langendorff-
perfused mouse heart. The failure to reduce myocardial IS
was mirrored by an absence of increase in the phosphorylation
of both proteins. Considering the control group as a reference
category, Akt phosphorylation was increased 1.08 ± 0.21 -fold
in the MIF 50 ng/mL group (P = 0.967) and 2.13 ± 0.37-fold
incremented in the IPC group (P = 0.046), whilst in the ERK
1/2 phosphorylation case, the higher dose of MIF showed an
increased to 1.52 ± 0.25 -fold (P = 0.358) and the IPC to
2.68 ± 0.38 -fold (P = 0.008), as illustrated in Fig. 5a and b,
respectively.
Discussion
In this study, the exogenous administration of physiological
concentrations of MIF in the 1–50 ng/mL range both before
ischemia and at reperfusion failed to reduce IS in an ex vivo
perfused murine model of IRI. Moreover, the application of a
higher dose in primary isolated cardiomyocytes did not have
any statistically significant impact on cell death. Finally, the
RISK signalling pathway was not activated when MIF was
administered in isolated-perfused hearts, consistent with the
absence of any IS-limiting effects. To our knowledge, this is
the first study demonstrating that the exogenous administra-
tion of MIF fails to confer cardioprotection in WT mice.
Previous evidence suggests that secreted myocardial MIF
release in response to I/R, acting in an autocrine/paracrine
fashion, can reduce the injury caused by an ischemic insult
followed by reperfusion [4, 8, 9]. However, in our isolated
mouse heart model, exogenous rMIF administration did not
afford the expected cardioprotection. Our seemingly contra-
dictory results did not contravene the previous ones and might
be explained by several reasons.
First, in terms of the source of MIF, prior studies have
assessed the involvement of endogenousMIF in cardioprotection
by suppressing its expression in KO models. These studies have
reported an increased damage in those genetic MIF deficiency
hearts (Mif−/−), whilst MIF restoration abolished this deleterious
effect [4, 8, 9].
Only one study reported the effect of MIF in old WT mice,
demonstrating that the exogenous MIF administration reduced
myocardial IS by the restoration of the impaired AMPK signal-
ing in these aged hearts [22]. Our study offers novel translational
insights on the cardioprotective effect of MIF in non-aged WT
mice, showing that different doses of MIF did not contribute to
reduce IS. Noteworthy, the low-dose of MIF resulted in a non-
significant reduction when applied before the ischemic insult,
without achieving statistical relevance. Hence, further studies
Fig. 3 Dose–response effect of exogenous rMIF administered upon
reperfusion on myocardial infarct size in the ex vivo isolated
Langendorff-perfused mouse heart model (%). Bar graph showing the
IS in all groups, expressed as mean ± SEM for infarct size (%), n = 5–6
per group. Overall P-value was <0.001, whilst in the post-hoc analysis,
the control group was compared to bradykinin (***P < 0.001), MIF 1 ng/
mL (P = 0.223), MIF 10 ng/mL (P = 0.412) and MIF 50 ng/mL
(P = 0.998). Abbreviations: IPC, ischemic preconditioning; MIF, macro-
phage migration inhibitory factor
Fig. 4 A supraphysiological concentration of rMIF does not increase
survival of isolated adult cardiomyocytes in normoxic and H/R condi-
tions. Bar graph showing the IS in all groups, expressed as mean ± SEM
for infarct size (%), n = 6 wells per group coming from 3 animals. Overall
P-value was 0.010. Comparisons between relevant groups did not show
statistically significant differences: normoxia vs normoxia with rMIF
1 μg/mL (24.0 ± 4.25 % vs 33.7 ± 5.60 %, P = 0.610), H/R vs H/R with
rMIF 1 μg/mL prior to the protocol (39.3 ± 3.94 % vs 47.6 ± 3.70 %,
P = 0.794); and H/R vs H/R with rMIF 1 μg/mL after the protocol
(39.3 ± 3.94 % vs 55.5 ± 6.85 %, P = 0.134). Abbreviations: H/R,
hypoxia/reoxygenation; MIF, macrophage migration inhibitory factor
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exploring even lower doses might be needed to elucidate if other
doses might confer cardioprotection. However, given that the
typical measurement of blood MIF levels in AMI patients is in
the order of 1.5–30 ng/mL [7], the clinical significance of any
observed protection at levels below this would be uncertain.
Alternatively, the impact of blocking endogenous MIF in an
IPCmodel could be tested. The recombinant bacterialMIF tested
in our study does not have these modifications and may thus not
have fully covered the potency ofMIF released in an IPC setting.
Future experiments could address such a possibility by blocking
MIF following cycles of IPC, e.g. with a neutralizing antibody
administered after the IPC cycles.
Second, in terms of the experimental protocol, the duration
of both ischemia and reperfusion influences the extent of tis-
sue injury [18, 25]. The cardioprotection conferred by MIF
has been reported in the specific experimental setting of short
IRI (usually 15–20 min of ischemia) [4]. When the period of
ischemia has been extended to 30 min followed by a longer
reperfusion, the IS-limiting effect of MIF has been lost [9, 18],
suggesting that the protection afforded by MIF might be also
dependent of the extent of ischemia. Moreover, other authors
have speculated that there is a dual-effect of MIF release
following an AMI [6], suggesting that an early rise of
cardiac-derived MIF (first MIF wave) might be responsible
for exerting cardioprotection in the setting of a brief ischemia,
followed by an activation of circulating leukocytes under lon-
ger ischemic insults, resulting in an increased expression of
MIF (second MIF wave) and other inflammatory molecules,
that enhance deleterious inflammatory responses [29]. This
hypothesis might be linked to other recent publications show-
ing that IRI damage progresses dynamically over time, fol-
lowing a bimodal pattern [30, 31].
Third, the doses were chosen based on MIF plasma levels [7,
17], as well as on those previously used by other research groups
[8, 22]. However, it might be possible that the appropriate dose
was not used. Prior publications showed a concentration of
20 μg/ml MIF to be cardio-depressant in the heart [9, 20, 21]
and a dose of 1μg/mL to restore increased IS following short IRI
damage [10]. However, the results obtained using the ex vivo
isolated heart model have been confirmed by the application of a
higher dose of MIF to isolated cells. Our viability studies clearly
show that such a high dose of rMIF did not increase cell survival.
Finally, whether the RISK pathway was activated after MIF ad-
ministration was also tested. Although Akt and ERK1/2 are not
the only pro-survival kinases conferring cardioprotection, wheth-
er they were activated by MIF is an important question, given
that previous studies have suggested that these kinases are impli-
cated in other pathological processes involving MIF [11–13].
Our results demonstrate that a lack of significant phosphorylation
of Akt and ERK1/2 is consistent with the lack of
cardioprotection, as well as with a previous study showing that
Akt was similar in WT and MIF KO hearts after IRI [8].
However, the activation of other pro-survival kinases also in-
volved in cardioprotection such as AMPK, cannot be ruled out.
Fig. 5 Effect of exogenous rMIF administration on Akt and ERK 1/2
phosphorylation Bar graph showing the percentage of phosphorylation
increased in all groups compared to the control group, expressed as
mean ± SEM (% of relative protein phosphorylation, normalized by its
total), n = 3 mice per group. a. Phospho-serine 473 Akt levels detected
after 15 min of MIF 50 ng/mL perfusion were increased in IPC compared
to control group (*P = 0.046), but no effect was detected on Akt phos-
phorylation in MIF group (P = 0. 967). b. Phospho-Thr202/Tyr204 ERK
1/2was increased in IPC compared to control group (**P = 0.008), but no
effect was detected on ERK 1/2 phosphorylation in MIF group
(P = 0.358). Abbreviations: IPC, ischemic preconditioning; MIF, macro-
phage migration inhibitory factor
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Several pre-clinical studies have reported a protective ef-
fect of endogenous MIF through the activation of a metabolic
pathway [4], the inhibition of pro-apoptotic JNK signalling [8]
and the oxidative stress reduction [9], thereby preventing
death following brief periods of myocardial IRI. Our results
did not challenge the fact that MIF mediates endogenous
cardioprotection in a first MIF wave [32], but reinforces the
idea that exogenous MIF (either from other cells in a second
MIF wave or from an exogenous administration) is not bene-
ficial in terms of IS reduction. However, we should not rule
out that the lack of free fatty acids in our Krebs-modified
buffer would have an impact in our results, since there is
strong evidence that MIF activates AMPK, which in turn in-
creases glucose uptake and glycolysis during ischemia and
also enhances fatty acid oxidation during reperfusion.
Despite the fact that no significant differences were found
on IS reduction after the use of rMIF at the doses studied, there
may still be room for translation. Further studies are needed,
particularly using in vivomodels to confirm our results as well
as using MIF agonists. For example, the cardioprotective role
of endogenousMIF following IPCmight be increased byMIF
agonists, such as MIF20 [15]. In addition, plasma MIF levels
are elevated in AMI patients and its use as a prognostic bio-
marker has been studied in preliminary studies, indicating a
predictive value for both IS and cardiac remodelling [17].
Finally, a specific pool of patients might benefit in the future
of the potential exogenous administration of MIF, such as
elderly patients with an impaired MIF-AMPK activation re-
sponse [22] and those with a low-expression 5/5MIF promot-
er genotype and susceptibility to ischemic tissue damage [15].
More attention should be paid to D-dopachrome tautomerase,
an enzyme that shares partial sequence and structural homol-
ogy with MIF, but which lacks certain pro-inflammatory and
negative inotropic features and has already demonstrated
cardioprotective properties [33].
Conclusions
Exogenous administration of rMIF both before ischemia and at
reperfusion in the doses studied failed to show cardioprotective
effects in an ex vivo perfused murine model of IRI, as well as in
primary isolated cardiomyocytes. Consistently, the RISK signal-
ling pathway was not activated by rMIF. Although these results
do not address the role of endogenous MIF after an ischemic
insult followed by reperfusion, they may limit the potential trans-
lational value of rMIF.
Acknowledgments This work was undertaken at UCLH/UCL who
received a proportion of funding from the Department of Health’s NIHR
Biomedical Research Centres funding scheme of which DM Yellon is a
Senior Investigator. Dr. Rossello has received support from the Fundacion
Alfonso Martin Escudero fellowship grant. Dr. Bernhagen was supported by
grants from the Deutsche Forschungsgemeinschaft (DFG) BE 1977/9-1,
SFB1123-A03, within the framework of the Munich Cluster for Systems
Neurology (EXC 1010 SyNergy), and by the Munich Heart Alliance/
German Center for Cardiovascular Research (MHA/DZHK). Dr. Stoppe re-
ceived support from the DFG (STO 1099/2-1).
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Ethical Approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed. All
procedures performed in studies involving animals were in accordance
with the ethical standards of the institution or practice at which the studies
were conducted. This article does not contain any studies with human
participants performed by any of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J
Med. 2007;357:1121–35.
2. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies
for myocardial ischemia/reperfusion injury. J Am Coll Cardiol.
2015;65:1454–71.
3. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhib-
itory factor in cardiovascular disease. Circulation. 2008;117:1594–
602.
4. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al.
Macrophage migration inhibitory factor stimulates AMP-activated
protein kinase in the ischaemic heart. Nature. 2008;451:578–82.
5. Pohl J, Hendgen-Cotta UB, Rammos C, Luedike P, Mull E, Stoppe
C, et al. Targeted intracellular accumulation of macrophage migra-
tion inhibitory factor in the reperfused heart mediates
cardioprotection. Thromb Haemost. 2015;115:200–12.
6. Liehn EA, Kanzler I, Konschalla S, Kroh A, Simsekyilmaz S,
Sönmez TT, et al. Compartmentalized protective and detrimental
effects of endogenous macrophage migration-inhibitory factor me-
diated by CXCR2 in a mouse model of myocardial ischemia/reper-
fusion. Arterioscler Thromb Vasc Biol. 2013;33:2180–6.
7. Rassaf T, Weber C, Bernhagen J. Macrophage migration inhibitory
factor in myocardial ischaemia/reperfusion injury. Cardiovasc Res.
2014;102:321–8.
8. Qi D, Hu X, Wu X, Merk M, Leng L, Bucala R, et al. Cardiac
macrophage migration inhibitory factor inhibits JNK pathway acti-
vation and injury during ischemia/reperfusion. J Clin Invest.
2009;119:3807–16.
9. Koga K, Kenessey A, Powell SR, Sison CP, Miller EJ, Ojamaa K.
Macrophage migration inhibitory factor provides cardioprotection
during ischemia/reperfusion by reducing oxidative stress. Antioxid
Redox Signal. 2011;14:1191–202.
10. Luedike P, Hendgen-Cotta UB, Sobierajski J, Totzeck M, Reeh M,
Dewor M, et al. Cardioprotection through S-nitros(yl)ation of mac-
rophage migration inhibitory factor. Circulation. 2012;125:1880–9.
Cardiovasc Drugs Ther
11. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, et al.
Macrophage migration inhibitory factor (MIF) promotes cell sur-
vival by activation of the Akt pathway and role for CSN5/JAB1 in
the control of autocrine MIF activity. Oncogene. 2007;26:5046–59.
12. ChatterjeeM, Borst O,Walker B, Fotinos A, Vogel S, Seizer P, et al.
Macrophage migration inhibitory factor limits activation-induced
apoptosis of platelets via CXCR7-dependent Akt signaling. Circ
Res. 2014;115:939–49.
13. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch
AE.Migration inhibitory factor mediates angiogenesis via mitogen-
activated protein kinase and phosphatidylinositol kinase. Circ Res.
2003;93:321–9.
14. Goetzenich A, Kraemer S, Rossaint R, Bleilevens C, Dollo F, Siry
L, et al. The role of macrophage migration inhibitory factor in
anesthetic-induced myocardial preconditioning. PLoS One.
2014;9:e92827.
15. Wang J, Tong C, Yan X, Yeung E, Gandavadi S, Hare AA, et al.
Limiting cardiac ischemic injury by pharmacological augmentation
of macrophage migration inhibitory factor-AMP-activated protein
kinase signal transduction. Circulation. 2013;128:225–36.
16. Stoppe C, Rex S, Goetzenich A, Kraemer S, Emontzpohl C,
Soppert J, et al. Interaction of MIF family proteins in myocardial
ischemia/reperfusion damage and their influence on clinical out-
come of cardiac surgery patients. Antioxid Redox Signal.
2015;23:865–79.
17. Chan W, White DA, Wang X-Y, Bai R-F, Liu Y, Yu H-Y, et al.
Macrophage migration inhibitory factor for the early prediction of
infarct size. J Am Heart Assoc. 2013;2:e000226.
18. Gao X-M, Liu Y, White D, Su Y, Drew BG, Bruce CR, et al.
Deletion of macrophage migration inhibitory factor protects the
heart from severe ischemia–reperfusion injury: a predominant role
of anti-inflammation. J Mol Cell Cardiol. 2011;50:991–9.
19. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and
postmyocardial infarction remodeling. Circ Res. 2004;94:1543–53.
20. Chagnon F, Metz CN, Bucala R, Lesur O. Endotoxin-inducedmyo-
cardial dysfunction: effects of macrophage migration inhibitory fac-
tor neutralization. Circ Res. 2005;96:1095–102.
21. Garner LB, Willis MS, Carlson DL, DiMaio JM,White MD,White
DJ, et al. Macrophage migration inhibitory factor is a cardiac-
derived myocardial depressant factor. Am J Physiol Heart Circ
Physiol. 2003;285:H2500–9.
22. Ma H, Wang J, Thomas DP, Tong C, Leng L, Wang W, et al.
Impaired macrophage migration inhibitory factor-AMP-activated
protein kinase activation and ischemic recovery in the senescent
heart. Circulation. 2010;122:282–92.
23. Bell RM, Yellon DM. Bradykinin limits infarction when adminis-
tered as an adjunct to reperfusion in mouse heart: the role of PI3K,
Akt and eNOS. J Mol Cell Cardiol. 2003;35:185–93.
24. Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion:
the Langendorff technique of isolated heart perfusion. J Mol Cell
Cardiol. 2011;50:940–50.
25. Rossello X, Hall AR, Bell RM, Yellon DM. Characterization of the
Langendorff perfused isolated mouse heart model of global ische-
mia–reperfusion injury: impact of ischemia and reperfusion length
on infarct size and LDH release. J Cardiovasc Pharmacol Ther.
2016;21(3):286–95.
26. Klein HH, Puschmann S, Schaper J, Schaper W. Vircho Archiv a
the mechanism of the Tetrazolium reaction in identifying experi-
mental myocardial infarction. Virchows Arch [Pathol Anat].
1981;393:287–97.
27. García-Prieto J, García-Ruiz JM, Sanz-Rosa D, Pun A, García-
Alvarez A, Davidson SM, et al. β3 adrenergic receptor selective
stimulation during ischemia/reperfusion improves cardiac function
in translational models through inhibition of mPTP opening in
cardiomyocytes. Basic Res Cardiol. 2014;109:422.
28. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG.
Improving bioscience research reporting: the ARRIVE guidelines
for reporting animal research. PLoS Biol. 2010;8:e1000412.
29. White DA, Fang L, ChanW,Morand EF, Kiriazis H, Duffy SJ, et al.
Pro-inflammatory action of MIF in acute myocardial infarction via
activation of peripheral blood mononuclear cells. PLoS One.
2013;8:e76206.
30. Fernández-Jiménez R, Sánchez-González J, Agüero J, García-
Prieto J, López-Martín GJ, García-Ruiz JM, et al. Myocardial ede-
ma after ischemia/reperfusion is not stable and follows a bimodal
pattern. J Am Coll Cardiol. 2015;65:315–23.
31. Fernández-Jiménez R, García-Prieto J, Sánchez-González J,
Agüero J, López-Martín GJ, Galán-Arriola C, et al .
Pathophysiology underlying the bimodal edema phenomenon after
myocardial ischemia/reperfusion. J Am Coll Cardiol. 2015;66:
816–28.
32. Dayawansa NH, Gao X-M, White DA, Dart AM, Du X-J. Role of
MIF in myocardial ischaemia and infarction: insight from recent
clinical and experimental findings. Clin Sci (Lond). 2014;127:
149–61.
33. Qi D, Atsina K, Qu L, Hu X, Wu X, Xu B, et al. The vestigial
enzyme D-dopachrome tautomerase protects the heart against is-
chemic injury. J Clin Invest. 2014;124:3540–50.
Cardiovasc Drugs Ther
